New hope for Tough-to-Treat lymphoma patients in clinical trial
NCT ID NCT03458260
Summary
This study tested a four-drug combination including pixantrone for adults with aggressive non-Hodgkin lymphoma that had returned or not responded to previous treatments. The main goal was to see if the treatment could shrink or eliminate the cancer, as measured by PET scans. Researchers also tracked side effects and whether the treatment helped patients become eligible for a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AZ Sint Jan
Bruges, Belgium
-
CH d'Avignon
Avignon, France
-
CH de Cornouaille
Quimper, France
-
CHRU de Lille
Lille, France
-
CHU Jean Minjoz
Besançon, France
-
CHU Lyon Sud
Lyon, France
-
CHU de Poitiers
Poitiers, France
-
CHU de Rouen
Rouen, France
-
CHU de Strasbourg
Strasbourg, France
-
CHU de Tours
Tours, France
-
CHU de la Conception
Marseille, France
-
Centre Hospitalier Annecy Genevois
Pringy, France
-
Centre Hospitalier William Morey
Chalon-sur-Saône, France
-
Centre Hospitalier de Jolimont
Haine-Saint-Paul, Belgium
-
Centre Hospitalier de la Côte Basque
Bayonne, France
-
Centre Lacassagne
Nice, France
-
Clinique Victor Hugo
Le Mans, France
-
Hopital La Pitié Salpétriere
Paris, France
-
Hôpital Haut-Lévèque
Bordeaux, France
-
Hôpital Robert Debré
Reims, France
-
Hôpital St louis
Paris, France
-
Institut Jules Bordet - Centre des tumeurs de l'ULB
Brussels, Belgium
Conditions
Explore the condition pages connected to this study.